Cancel anytime
Chromadex Corp (CDXC)CDXC
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/12/2024: CDXC (5-star) is a STRONG-BUY. BUY since 8 days. Profits (23.72%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Strong Buy |
Historic Profit: 108.88% | Upturn Advisory Performance 4 | Avg. Invested days: 30 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 11/12/2024 |
Type: Stock | Today’s Advisory: Strong Buy |
Historic Profit: 108.88% | Avg. Invested days: 30 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 11/12/2024 | Upturn Advisory Performance 4 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 535.45M USD |
Price to earnings Ratio 350.5 | 1Y Target Price 7.7 |
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Volume (30-day avg) 1896718 | Beta 1.88 |
52 Weeks Range 1.32 - 7.58 | Updated Date 11/11/2024 |
Company Size Small-Cap Stock | Market Capitalization 535.45M USD | Price to earnings Ratio 350.5 | 1Y Target Price 7.7 |
Dividends yield (FY) - | Basic EPS (TTM) 0.02 | Volume (30-day avg) 1896718 | Beta 1.88 |
52 Weeks Range 1.32 - 7.58 | Updated Date 11/11/2024 |
Earnings Date
Report Date 2024-10-31 | When AfterMarket |
Estimate 0.01 | Actual 0.02 |
Report Date 2024-10-31 | When AfterMarket | Estimate 0.01 | Actual 0.02 |
Profitability
Profit Margin 1.62% | Operating Margin (TTM) 6.26% |
Management Effectiveness
Return on Assets (TTM) 0.51% | Return on Equity (TTM) 4.82% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE 350.5 | Forward PE 50 |
Enterprise Value 467140235 | Price to Sales(TTM) 5.84 |
Enterprise Value to Revenue 5.1 | Enterprise Value to EBITDA 240.05 |
Shares Outstanding 76383296 | Shares Floating 49384108 |
Percent Insiders 35.39 | Percent Institutions 22.68 |
Trailing PE 350.5 | Forward PE 50 | Enterprise Value 467140235 | Price to Sales(TTM) 5.84 |
Enterprise Value to Revenue 5.1 | Enterprise Value to EBITDA 240.05 | Shares Outstanding 76383296 | Shares Floating 49384108 |
Percent Insiders 35.39 | Percent Institutions 22.68 |
Analyst Ratings
Rating 4.6 | Target Price 5.17 | Buy 2 |
Strong Buy 3 | Hold - | Sell - |
Strong Sell - |
Rating 4.6 | Target Price 5.17 | Buy 2 | Strong Buy 3 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Chromadex Corp: A Comprehensive Overview
Company Profile:
History and Background: ChromaDex Corp. (CDXC) is a California-based bioscience company founded in 1999. Initially, the company focused on the discovery and development of natural products for health and wellness. However, it shifted its focus to the development and commercialization of bioavailable ingredients for the dietary supplement, food, beverage, and cosmetic industries in 2010.
Core Business Areas:
- Ingredient Development: ChromaDex focuses on identifying and developing natural compounds with scientifically-supported health benefits. Some of its key ingredients include Niagen® (nicotinamide riboside), pTeroPure® (pterostilbene), and TruNature® (mixed carotenoids).
- Contract Research & Manufacturing Services: ChromaDex offers contract research and manufacturing services to the food and supplement industry, leveraging its expertise in ingredient development, bioavailability, and manufacturing processes.
Leadership and Structure: The company is led by President and CEO Rob Fried, a veteran in the nutritional supplement industry. He is supported by a team of experienced executives with expertise in areas like product development, research, and sales. ChromaDex operates through a single business segment, focusing on its bioavailable ingredient platform.
Top Products and Market Share:
- Top Products:
- Niagen®: This patented form of vitamin B3 is claimed to boost NAD+ levels and potentially offer various health benefits, including cognitive function improvement and aging support.
- pTeroPure®: A highly bioavailable form of pterostilbene, an antioxidant with potential anti-inflammatory and longevity benefits.
- TruNature® Mixed Carotenoids: A blend of naturally-sourced carotenoids with antioxidant properties.
- Market Share: ChromaDex is a leading supplier of NAD+ boosters and pterostilbene in the global market, with significant market share in the US and other regions. However, it faces competition from other ingredient manufacturers and dietary supplement brands.
Total Addressable Market:
The global market for dietary supplements reached approximately USD 125 billion in 2022 and is projected to grow at a CAGR of over 9% by 2027. The aging population, rising healthcare costs, and growing focus on preventative health are driving this growth. ChromaDex aims to capture a significant share of this market through its ingredient sales and contract research services.
Financial Performance:
- Revenue and Profitability: ChromaDex has experienced steady revenue growth in recent years, with total revenue reaching USD 45.3 million in FY 2022. However, the company has not yet achieved consistent profitability, reporting a net loss of USD 6.5 million in FY 2022.
- Financial Health: ChromaDex has a relatively healthy balance sheet with sufficient cash reserves. However, it also has a considerable amount of debt, which may impact its financial flexibility.
Dividends and Shareholder Returns:
- Dividend History: ChromaDex does not currently pay dividends to shareholders.
- Shareholder Returns: Although the company's stock price has been volatile in recent years, it has delivered positive returns for long-term investors. The stock price has increased by over 200% in the past five years.
Growth Trajectory:
- Historical Growth: ChromaDex has shown strong revenue growth over the past few years, primarily driven by increased demand for its flagship ingredient, Niagen®.
- Future Growth: The company expects continued growth driven by the rising popularity of NAD+ boosters and its expansion into new markets and product categories. Recent product launches and strategic partnerships also contribute to its growth prospects.
Market Dynamics:
- Industry Trends: The dietary supplement industry is experiencing tremendous growth, fueled by increasing consumer awareness of health and wellness. Natural ingredients, personalized nutrition, and scientifically-backed products are key trends in this sector.
- Competitive Landscape: ChromaDex faces competition from other ingredient suppliers, including the likes of DSM, Glanbia, and Lonza, as well as various dietary supplement brands that develop their own products.
Competitors:
- Key competitors include:
- DSM (DSM)
- Glanbia (GNP)
- Lonza (LONN)
- Nature's Bounty Co. (NBTY)
- GNC Holdings Inc. (GNC)
- While ChromaDex holds a strong position in the NAD+ booster and pterostilbene markets, its competitors offer a broader range of ingredients and finished products, posing a significant challenge.
Recent Acquisitions:
- ChromaDex acquired Elysium Health, a longevity-focused supplement company, in April 2021. This acquisition brought the Basis® cellular health supplement line into ChromaDex's portfolio, expanding its product offerings and distribution channels.
- The acquisition aligns with ChromaDex's strategy to focus on NAD+ boosters and other ingredients with scientifically-backed health benefits, catering to the growing demand for products that address age-related health concerns.
AI-Based Fundamental Rating:
Based on an AI analysis, ChromaDex receives a score of 7.5 out of 10. This rating reflects the company's strong product portfolio, promising growth potential, and healthy balance sheet. However, factors like profitability challenges, volatile stock price, and competitive pressure contribute to a moderately higher risk profile.
Sources and Disclaimers:
This overview utilizes information from ChromaDex's corporate website, financial statements, investor relations materials, industry reports, and news articles. Please note that this information is for general educational purposes and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Chromadex Corp
Exchange | NASDAQ | Headquaters | Los Angeles, CA, United States |
IPO Launch date | 2008-07-15 | CEO & Director | Mr. Robert N. Fried |
Sector | Consumer Defensive | Website | https://www.chromadex.com |
Industry | Packaged Foods | Full time employees | 106 |
Headquaters | Los Angeles, CA, United States | ||
CEO & Director | Mr. Robert N. Fried | ||
Website | https://www.chromadex.com | ||
Website | https://www.chromadex.com | ||
Full time employees | 106 |
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.